Bezlotoxumab
ApprovedTerminated 0 watching 1 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Clostridia Difficile Colitis
Conditions
Clostridia Difficile Colitis, Clostridium; Sepsis
Trial Timeline
Aug 19, 2019 → May 23, 2022
NCT ID
NCT03756454About Bezlotoxumab
Bezlotoxumab is a approved stage product being developed by Merck for Clostridia Difficile Colitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT03756454. Target conditions include Clostridia Difficile Colitis, Clostridium; Sepsis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04626947 | Approved | Terminated |
| NCT03937999 | Approved | Terminated |
| NCT03756454 | Approved | Terminated |